$216.97 meals Payment -- Takeda Pharmaceuticals to Dr. James Wilson
Takeda Pharmaceuticals provides $216.97 in meals to Gastroenterologist James Wilson for Imbruvica.
This page provides a detailed analysis of a $216.97 meals payment from Takeda Pharmaceuticals to Dr. James Wilson. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $216.97 |
| Payment Type | meals |
| Payment Nature | Food and Beverage |
| Pharmaceutical Company | Takeda Pharmaceuticals |
| Physician | Dr. James Wilson |
| NPI Number | 1933272063 |
| Physician Specialty | Gastroenterology |
| Location | City, SC |
| Date of Payment | 2026-03-28 |
| Related Drug/Device | Imbruvica |
| Conflict Assessment | Low -- Routine |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Takeda Pharmaceuticals made a $216.97 meals payment to James Wilson, a Gastroenterology specialist in City, SC. The payment was associated with Imbruvica. The payment of $216.97 to Dr. James Wilson was for meals provided by Takeda Pharmaceuticals. This payment occurred on March 28, 2026, and is associated with the drug Imbruvica. The payment falls under the 'Food and Beverage' category, specifically for meals.
Patient Guidance: What This Payment Means for You
This payment was for meals provided by a pharmaceutical company and is not directly related to your personal medical care. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
For Gastroenterologists, payments for meals are common and generally considered low value, often associated with educational events or discussions about medications.
Regulatory Context: Sunshine Act Requirements
Payments for meals by pharmaceutical companies to physicians are subject to disclosure under the Open Payments program to ensure transparency in healthcare.
Related Topics
This payment is related to the following healthcare transparency topics:
- meals
- food-and-beverage
- takeda-pharmaceuticals
- james-wilson
- imbruvica
- gastroenterology
Understanding meals Payments
Food and beverage payments cover meals provided to physicians during pharmaceutical sales representative visits, medical conferences, and educational events. While individual meal payments tend to be small (often under $100), research published in JAMA Internal Medicine has shown that even modest meals can be associated with changes in prescribing behavior. Meal payments are the most common type of pharmaceutical payment to physicians.
Frequently Asked Questions About This Payment
What was this $216.97 payment for?
This was a meals payment of $216.97 from Takeda Pharmaceuticals to James Wilson, categorized as "Food and Beverage". It was associated with Imbruvica. The payment was reported under the Sunshine Act (CMS Open Payments).
Does James Wilson accept pharmaceutical money?
Yes, James Wilson received this $216.97 payment from Takeda Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view James Wilson's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this meals payment?
A meals payment of $216.97 is generally routine and common in the industry. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Gastroenterology?
To compare this payment against Gastroenterology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Gastroenterology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about James Wilson's relationship with Takeda Pharmaceuticals?
The payment amount is relatively small, suggesting it was for a single meal or a small group. This $216.97 meals payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Gastroenterology?
The payment date is in the future (2026), which is unusual for reported historical data.
What should patients do after learning about this payment?
This payment was for meals provided by a pharmaceutical company and is not directly related to your personal medical care.
What else should I know about this meals payment?
The payment is linked to a specific drug, Imbruvica, indicating a potential educational or promotional context.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.